Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
Date: July 17, 2017
Issue #:
1525Summary:
The FDA has approved telotristat ethyl (Xermelo–
Lexicon), a tryptophan hydroxylase inhibitor, for
use in combination with a somatostatin analog
(SSA) for treatment of carcinoid syndrome diarrhea
inadequately controlled with SSA therapy alone.
Telotristat ethyl is the first oral drug to be approved
in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: lanreotide octreotide Sandostatin Somatuline Autogel Somatuline Depot Telotristat ethyl Xermelo Source Type: research